Valeant Pharmaceuticals nears deal to buy Bausch & Lomb for $9 billion
Canada's Valeant Pharmaceuticals International is nearing a deal to acquire eye care company Bausch & Lomb Holdings Inc. from Warburg Pincus LLC for about $9 billion, a person familiar with the matter said on Friday. Fri, 24 May 2013 23:08:17 -0700

Arena Pharmaceuticals to Present at Two Upcoming Investor Conferences
SAN DIEGO, May 24, 2013 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that the company is scheduled to present a corporate overview at the following investor conferences: Deutsche ... Fri, 24 May 2013 05:00:00 -0700

Aegerion Pharmaceuticals Announces Webcast of Investor Presentations at Upcoming Conferences
CAMBRIDGE, Mass. -- Aegerion Pharmaceuticals, Inc. , an emerging biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat debilitating and often fatal rare ... Fri, 24 May 2013 05:00:00 -0700

Auxilium Pharmaceuticals, Inc. To Present At The Deutsche Bank Health Care Conference
CHESTERBROOK, Pa., May 24, 2013 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (Nasdaq: AUXL) today announced that executive management will participate in the Deutsche Bank Health Care Conference to be ... Fri, 24 May 2013 04:00:00 -0700

Research and Markets: Generic Pharmaceuticals (Global) Analysis Report
Research and Markets has announced the addition of the "Generic Pharmaceuticals " report to their offering. Fri, 24 May 2013 02:18:00 -0700

Vanda Pharmaceuticals Named the 2013 Life Science Firm of the Year by the Tech Council of Maryland
WASHINGTON, May 23, 2013 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ:VNDA) today announced that the company has been named the 2013 Life Science Firm of the Year by the Tech Council of Maryland ... Thu, 23 May 2013 19:00:00 -0700

Agree To Buy Regeneron Pharmaceuticals At $165, Earn 9.8%
Investors eyeing a purchase of Regeneron Pharmaceuticals, Inc. (NASD: REGN) shares, but tentative about paying the going market price of $256.05/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the January 2015 put at the $165 strike, which has a bid at the time of this writing of $16.10 ... Thu, 23 May 2013 11:20:05 -0700

Spectrum Pharmaceuticals to Present Corporate Update at the Deutsche Bank 38th Annual Health Care Conference in Boston ...
Spectrum Pharmaceuticals , a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced that an overview of the Company's business strategy and commercial and development-stage programs will be given at the Deutsche Bank 38th Annual Health Care Conference being held at The Westin Boston Waterfront Hotel ... Thu, 23 May 2013 04:00:00 -0700

Clinical Data on TetraLogic Pharmaceuticals’ Smac Mimetic Birinapant to Be Presented at ASCO
TetraLogic Pharmaceuticals, a biopharmaceutical company developing novel small molecule Smac mimetic drugs to treat cancer, today announced that data from two clinical studies investigating its lead Smac mimetic drug candidate birinapant will be presented at the 2013 Annual Meeting of the American Society of Clinical Oncology being held May 31 – June 4, 2013 in Chicago, IL. Wed, 22 May 2013 05:37:00 -0700

Syros Pharmaceuticals Appoints Eric R. Olson, Ph.D. as Chief Scientific Officer
Syros Pharmaceuticals, a newly launched company harnessing breakthroughs in gene control to revolutionize the treatment of cancer and other diseases, announced today that Eric R. Olson, Ph.D., has joined the company as its Chief Scientific Officer. Wed, 22 May 2013 05:30:00 -0700